Viquidacin

Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L[1].

Product Specifications

CAS Number

904302-98-3

Product Name Alternative

NXL 101

UNSPSC

12352005

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/viquidacin.html

Smiles

[H][C@@](C1)(C(O)=O)[C@@](CC[C@]([H])(O)C2=C(F)C=NC3=C2C=C(OC)C=C3)([H])CCN1CCSC4=CC=CS4

Molecular Formula

C25H29FN2O4S2

Molecular Weight

504.64

References & Citations

[1]Black MT, et al., Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother. 2008 Sep;52 (9) :3339-49.